H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod [Yahoo! Finance]
Armata Pharmaceuticals, Inc. (ARMP)
Company Research
Source: Yahoo! Finance
Armata Pharmaceuticals, Inc. (NYSEAM: ARMP is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after the FDA designated AP-SA02 as a Qualified Infectious Disease Product, providing extra regulatory support as the business gets ready for its Phase 3 superiority research, which is set for the second half of 2026. Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) declared on February 23 that its intravenous Staphylococcus aureus multi-phage candidate, AP-SA02, has been given Qualified Infectious Disease Product (QIDP) classification by the U.S. FDA. Its usage as an adjuvant treatment for complex bacteremia brought on by both methicillin-sensitive
Show less
Read more
Impact Snapshot
Event Time:
ARMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARMP alerts
High impacting Armata Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARMP
News
- Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02PR Newswire
- Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus [Yahoo! Finance]Yahoo! Finance
- Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureusPR Newswire
ARMP
Earnings
- 11/12/25 - Miss
ARMP
Sec Filings
- 2/23/26 - Form 8-K
- 1/26/26 - Form SCHEDULE
- 1/26/26 - Form 8-K
- ARMP's page on the SEC website